CD4 and CD8 T-Lymphocyte Recognition of Prostate Specific Antigen in Granulomatous Prostatitis

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of immunotherapy

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002371-200403000-00007PMID 14770085
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor‐specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines

  2002cited by this paper
• Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy1

  2001cited by this paper
• Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study.

  2000cited by this paper
• Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen.

  2000cited by this paper
• Generation of PSA‐reactive effector cells after vaccination with a PSA‐based vaccine in patients with prostate cancer

  2000cited by this paper
• A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

  2000cited by this paper
• PSA is a candidate self‐antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome

  2000cited by this paper
• Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro1

  2000cited by this paper
• IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis.

  2000cited by this paper
• IL-1β AND TNF-α IN PROSTATIC SECRETIONS ARE INDICATORS IN THE EVALUATION OF MEN WITH CHRONIC PROSTATITIS

  2000cited by this paper
• Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy.

  1999cited by this paper
• Susceptibility to multiple sclerosis mediated by HLA-DRB1 is influenced by a second gene telomeric of the TNF cluster.

  1999cited by this paper
• Recognition of prostate‐specific antigenic peptide determinants by human CD4 and CD8 T cells

  1998influential reference
• Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.

  1998cited by this paper
• Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

  1998cited by this paper
• Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine

  1998cited by this paper
• Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer.

  1998cited by this paper
• Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome.

  1998cited by this paper
• Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy.

  1997cited by this paper
• Tumor antigens recognized by T cells.

  1997cited by this paper
• In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.

  1997cited by this paper
• Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.

  1997cited by this paper
• Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer.

  1997cited by this paper
• Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins.

  1997cited by this paper
• Induction of human cytotoxic T lymphocytes specific for prostate‐specific antigen

  1997cited by this paper
• Cancer vaccines based on the identification of genes encoding cancer regression antigens.

  1997cited by this paper
• Chronic prostatitis: results of an Internet survey.

  1996cited by this paper
• Helper T Cells Infiltrating Human Renal Cell Carcinomas Have the Phenotype of Activated Memory‐Like T Lymphocytes

  1995cited by this paper
• A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

  1995cited by this paper
• Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor.

  1995cited by this paper
• Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid.

  1995cited by this paper
• Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes.

  1994cited by this paper
• An immunohistological study of granulomatous prostatitis

  1991cited by this paper
• Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.

  1991cited by this paper
• Three predominant proteins secreted by the human prostate gland

  1988cited by this paper
• The clinical spectrum of granulomatous prostatitis: a report of 200 cases.

  1987cited by this paper
• HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes.

  1982cited by this paper
• Prostate antigen: a marker for human prostate epithelial cells.

  1981cited by this paper
• Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study.

  1979cited by this paper

• Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence?

  2023cites this paper
• Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia

  2023cites this paper
• Health inequity drives disease biology to create disparities in prostate cancer outcomes

  2022cites this paper
• Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment

  2021cites this paper
• Immunomodulatory effect of diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4+T/IL-17 and TGF-β1/ERK pathways

  2020cites this paper
• Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines

  2019cites this paper
• TGF-BETA IN THE NATURAL HISTORY OF PROSTATE CANCER

  2019cites this paper
• Advancements in Tumor Immunotherapy and Cancer Vaccines 38 preclinical studies

  2017cites this paper
• Immunological Mechanisms Underlying Chronic Pelvic Pain and Prostate Inflammation in Chronic Pelvic Pain Syndrome

  2017cites this paper
• Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design

  2015cites this paper
• Changes in Immune Markers for Prostate Cancer Patients Pre and Post-operation

  2014cites this paper
• The Link Between Benign Prostatic Hyperplasia and Inflammation

  2013cites this paper
• Challenges to Prostate Cancer Immunotherapy

  2012cites this paper
• Initiation and regulation of effector T cell responses in the prostate

  2011cites this paper
• An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate

  2011cites this paper
• TGF-β signalling and immunity in prostate tumourigenesis

  2010cites this paper
• Prostatakarzinom - Epidemiologie in Österreich, Risikofaktoren, Pathologie, hormonelle Regulation und Tumorbiologie

  2010cites this paper
• Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+

  2009cites this paper
• Cutting Edge: Permissive MHC Class II Allele Changes the Pattern of Antitumor Immune Response Resulting in Failure of Tumor Rejection1

  2009cites this paper
• T-cell recognition of prostatic peptides in men with chronic prostatitis/chronic pelvic pain syndrome.

  2009cites this paper
• [Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].

  2007cites this paper
• Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?

  2007cites this paper
• Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase

  2007cites this paper
• Chronische Inflammation als Promotor- und Behandlungstarget bei benigner Prostatahyperplasie (BPH) und beim Prostatakarzinom

  2007cites this paper
• Vaccination therapy in prostate cancer

  2007cites this paper
• Delivery of DNA vaccines against cancer

  2006cites this paper
• Developing Models to Facilitate the Appropriate Selection and Effective Targeting of Candidate Antigens for Specific Cellular Immunotherapy of Prostate Cancer

  2006cites this paper
• Induction of t-cell responses against PSA by plasmid DNA immunization

  2005cites this paper
• INDUCTION OF T-CELL RESPONSES AGAINST PSA BY

  2005cites this paper
• Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens

  2005cites this paper
• Identification of HLA-DRB1*1501–Restricted T-cell Epitopes from Prostate-Specific Antigen

  2005cites this paper
• Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

  2005cites this paper
• Combining a Recombinant CancerVaccinewith Standard Definitive Radiotherapy in Patientswith Localized Prostate Cancer

  2005cites this paper
• CD8-based T cell vaccination and CD4 T cell responses in prostate cancer.

  2005cites this paper
• Identification of Antigen-Specific IgG in Sera from Patients with Chronic Prostatitis

  2004cites this paper
• Granulomatous prostatitis linked to HLA-DRB1*1501.

  2004cites this paper